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Abstract
Background
Clinical trials conducted in Africa often require substantial investments to support trial cen-
tres and public health facilities. Trial resources could potentially generate benefits for rou-
tine health service delivery but may have unintended consequences. Strengthening ethical
practice requires understanding the potential effects of trial inputs on the perceptions and
practices of routine health care providers. This study explores the influence of malaria vac-
cine trials on health service delivery in Ghana, Kenya and Burkina Faso.
Methods
We conducted: audits of trial inputs in 10 trial facilities and among 144 health workers; indi-
vidual interviews with frontline providers (n=99) and health managers (n=14); and group dis-
cussions with fieldworkers (n=9 discussions). Descriptive summaries were generated from
audit data. Qualitative data were analysed using a framework approach.
Results
Facilities involved in trials benefited from infrastructure and equipment upgrades, support
with essential drugs, access to trial vehicles, and placement of additional qualified trial staff.
Qualified trial staff in facilities were often seen as role models by their colleagues; assisting
with supportive supervision and reducing facility workload. Some facility staff in place before
the trial also received formal training and salary top-ups from the trials. However, differential
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access to support caused dissatisfaction, and some interviewees expressed concerns
about what would happen at the end of the trial once financial and supervisory support
was removed.
Conclusion
Clinical trials function as short-term complex health service delivery interventions in the fa-
cilities in which they are based. They have the potential to both benefit facilities, staff and
communities through providing the supportive environment required for improvements in
routine care, but they can also generate dissatisfaction, relationship challenges and demor-
alisation among staff. Minimising trial related harm and maximising benefits requires careful
planning and engagement of key actors at the outset of trials, throughout the trial and on
its’ completion.
Background
Over recent decades increased funding has been made available for malaria clinical trials
(CTs), especially late stage vaccine trials, in sub-Saharan Africa [1, 2]. The public health sys-
tems in many of the countries in which these CTs have been implemented are weak with the
quality of health services affected by several supply and demand side constraints including the
high cost of care, poor physical accessibility of health facilities, drug stock-outs, lack of essential
equipment, and shortages of health professionals [3–5].
A requirement for the ethical conduct of CTs is that participants in the trial receive stan-
dards of care which meet local and international guidelines such as Good Clinical and Labora-
tory Practices [6–8]. To conduct CTs in low resource settings, substantial investments are often
required to upgrade service provision and health facilities to meet these standards. Investments
in service provision and facility infrastructure can include the purchase of highly specialized
medical equipment, the development of fully equipped laboratories, investment in transport
and vaccine ‘cold chain’ systems, and the construction of additional buildings [7, 9–11]. To ad-
dress health workforce challenges, CTs often hire additional personnel and provide training
and incentives to those already in post [12, 13].
With such inputs, CTs have the potential to generate benefits for local communities and
there is a growing body of literature documenting local community perceptions and experi-
ences of CTs [2, 9, 10, 14–18]. These studies suggest CT benefits to communities include im-
proved standards of care (ancillary care), better health outcomes due to continuous disease
surveillance, and improved access to health facilities. At the research programme level, CT in-
vestments contribute to capacity development (both human resource and infrastructure)
which in the long-run makes such centres become better contenders for future CTs [2, 11, 19].
However, for large multi-country studies, implementation challenges include translation of in-
formed consent documents, community perceptions of risks and benefits, comprehension of
technical procedures and community engagement strategies that are culturally acceptable [2, 9,
10, 14–18].
A few recent studies suggest that during their conduct, clinical trials can contribute to the
quality of routine healthcare provided to trial participants [12, 20], and investments towards
upgrading health facilities to CT standards create the necessary platform to attract and conduct
other research in future [2, 11, 19]. On the other hand, anecdotal information suggests that
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clinical trials may negatively impact routine healthcare delivery by diverting resources. Little is
known about if and how the inputs of CTs affect the provision of routine health care for non-
participating children and adults attending CT facilities, or how the providers of routine care
in such settings perceive and are affected by these inputs. Furthermore, little attention has been
paid to potential post-trial effects on the provision of routine health care. Understanding the
possible post-trial positive and negative consequences for routine care could contribute to
changes in the way clinical trials are planned and implemented, ultimately strengthening
ethical practice.
To increase our understanding of the impact of clinical trials on the delivery of health care
to children in low resource settings, a consortium of African and European experts in CTs, so-
cial science, community engagement and public health was established in January 2011. The
consortium was led by the Kintampo Health Research Centre (KHRC) in Ghana and involved
partners from the KEMRI-Wellcome Trust Research Programme (KWTRP) in Kenya, the
Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Ouagadougou in
Burkina Faso, and the London School of Hygiene and Tropical Medicine (LSHTM) in the UK.
The consortium developed a multi-site, multi-component study whose overall aim was to gain
insight into the impact of clinical trials on health services in three countries in sub-Saharan Af-
rica (Ghana, Kenya and Burkina Faso), especially with regards to the quality of services deliv-
ered to children. We recognise that in many clinical trial settings, including those involved in
the consortium, the expertise and resources that are required to conduct trials ethically mean
that certain sites often run a number of trials over time and sometimes concurrently. Thus at
any given point of time, health care in facilities may be influenced by historical and on-going
trials. In this paper, we focus on the specific inputs and perceived impacts related to two major
malaria vaccine trials in three sites. Although we recognise that these factors will be influenced
by the trial context or ‘platform’ of research activities and relationships, and mention this
where relevant, this platform is the focus of additional analysis currently in progress.
Study setting and health system context
The public health systems in Ghana, Kenya and Burkina Faso are often constrained by inade-
quate basic health infrastructure, poor road networks, and other service delivery barriers such
as drug shortages, long distances to facilities, high cost of treatment, and staff shortages [21,
22]. Further health workforce challenges, particularly for rural health facilities, include high
staff workload, inappropriate skills-mix and high staff-patient ratio [23, 24]. In all three coun-
tries, total government expenditure on health as a percentage of gross domestic product is well
below the 2001 Abuja declaration target of 15% [25], and the health systems depend largely on
external donor funding and out-of-pocket payments through health insurance or at point of
care payment [26, 27]. At the time of this study, national health sector reforms being imple-
mented in the three countries included a health insurance scheme (NHIS) in Ghana, a direct
facility funding initiative (HSSF) in Kenya, and a primary health care subsidy initiative to im-
prove skilled delivery in Burkina Faso [28–30].
The KHRC in Ghana, the KWTRP in Kenya and the CNRFP in Burkina Faso are all well-
established research centres conducting multi-disciplinary research on malaria and other infec-
tious diseases in sub-Saharan Africa. Each of these research centres has established clinical trial
facilities and a health demographic surveillance system (HDSS) from which potential-research
participants are drawn. Each centre has over 5 years of experience in conducting malaria clini-
cal trials [31–39]. These centres are all located in rural or peri-urban settings, characterised by
low literacy and high poverty levels, with subsistence farming as the main economic activity
(see Table 1).
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In all three countries the research centres have a close collaboration with the Ministry of
Health and provide support to health facilities where clinical research is undertaken. For in-
stance, in Ghana the children’s ward in Kintampo North Municipal Hospital has over the years
since the establishment of the KHRC received hospital equipment and upgrades from previous
malaria clinical trials [31, 40]. In Kenya, through the MoH collaboration, KWTRP supports
both children and adult wards in Kilifi County Hospital with the provision of medicines, sup-
plies and diagnostic tests [20, 41]. In Burkina Faso, part of the hospital building in Banfora was
converted to a clinical trial facility, where all CNRFP clinical trial activities are conducted. Else-
where, we are analysing the operation of these research centres and the implications of such
long-term engagements. The focus of this paper is health providers’ and managers’ perceptions
of the impact of on-going malaria vaccine trials (MVTs) on routine health service delivery in
facilities where MVTs were being implemented.
At the time of the study, the KHRC-Ghana and KWTRP-Kenya were conducting RTS,S
phase III malaria vaccine trials while the CNRFP in Burkina Faso was undertaking a GMZ2
phase II malaria vaccine trial. These trials involved assessing the safety and efficacy of vaccines
against malaria among infants and children [42, 43]. They were conducted in rural government
health facilities including community clinics, dispensaries, health centres and referral hospitals
and involved existing Ministry of Health (MoH) staff as well as specifically recruited trial staff
(see Table 2). In Ghana and Burkina Faso the MVTs were conducted in facilities that had been
involved in previous research centre activities. By contrast, in Kenya all of the MVT activities
(apart from the provision of clinical care to referral patients) were conducted in health facilities
with no previous involvement with research centre activities (Table 2). In all three countries a
range of stakeholders were consulted by MVT principal investigators, to assist in selecting the
health facilities to be involved in the trial, and to discuss the types of resources required for
Table 1. Research centers description.
Characteristics of trial
centres
KHRC (Ghana) KWTRP (Kenya) CNRFP (Burkina Faso)
Year of establishment 1994 1989 1983
Location Brong Ahafo Region, middle belt
of Ghana
Kiliﬁ County, Kenyan Coast Ouagadougou
Institutional size
(research capacity) year
2012/13
Over 600 staff (120 researchers) Over 800 staff (77 researchers) Over 150 staff (57 researchers)
Year clinical trial facility
established
2005 2007 2009
Examples of malaria
clinical trials conducted
RTS,S phase II and phase III
malaria vaccine trials,
Artemether-Lumefantrine
malaria drug trial
RTS,S phase II and phase III malaria
vaccine trials, TrapVac trial, ME-Trap
vaccine trial, Artemether-Lumefantrine
malaria drug trial
Phase IIb GMZ 2 malaria vaccine trial, Phase
IIb ME-TRAP candidate malaria vaccine trial,
Phase Ib MSP 3 candidate vaccine,
Artemether-Lumefantrine malaria drug trial
Malaria transmission High endemic region Low endemic region Hyper-endemic with seasonal malaria
transmission
Poverty levels 25% of its population in the
lowest wealth quintile
Over 60% of the population living below
poverty lines
Estimated to be at 40%
Literacy levels Over 52% with no formal
education
About 45% of adults unable to read and
write
Estimated to be at 21.8%
Main economic activities Subsistence farming Subsistence farming, small scale ﬁshing
and mining
Subsistence farming, craft industries, ﬁshing
and local manufacturing
Predominant group(s) Akans (bonos) and Mos,
Wangaras, Gonja and Mamprusi
(Northern region)
Mijikenda Goin, Karaboro and the Turka
doi:10.1371/journal.pone.0124554.t001
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MVT implementation in the selected facilities. Discussions were also held to identify how
MoH staff working in the selected facilities might become involved in the MVTs and how such
staff would be supported.
The principal investigators (PIs) of the malaria vaccine trials in Ghana and Burkina Faso
were also the PIs for this current study of the effect of the trial activities on provider percep-
tions and practices, but the study activities were developed and implemented by the social sci-
ence research teams at each site. In Kenya, the PIs for this study were not members of the
malaria vaccine trial, but were from the same institution, the KWTRP.
Methods
An initial partners’meeting was held in Kintampo, Ghana in March 2012 to develop a com-
mon study methodology across all three sites to allow for inter-site descriptive comparisons.
To describe the malaria vaccine trial inputs and explore their impact on the perceptions and
practices of these health managers and health care providers we employed both quantitative
(health facility and human resources audits) and qualitative (in-depth interviews and focus
group discussion) methods. Data were collected between May 2012 and June 2013 by teams of
trained research officers and fieldworkers in each country using the agreed common data
Table 2. Description of the malaria vaccine trials.
Trial details Ghana: RTS,S phase III malaria
vaccine trial
Kenya: RTS,S phase III malaria
vaccine trial
Burkina Faso: GMZ2 phase II b
malaria vaccine trial
Trial duration March 2009 – January 2014 May 2009 – January 2014 April 2011 – July 2013
Children recruited (age/
number)
1,333 healthy children: 5–17 months
(n = 1002), 6–12 weeks (n = 331)
904 healthy children: 5–17 months
(n = 600), 6–12 weeks (n = 304)
580 healthy children:12–60 months
(n = 580)
Trial location Kintampo North and Kintampo South
Districts
Ganze District, Kiliﬁ County Banfora District
Government facilities
involved; distance from
clinical trial facility (km/
m)*
3 health centres: 19 km, 47 km and 51
km from KHRC
2 dispensaries; 27 km and 38 km from
KWTRP
- 2 community clinics (CSPS)a; 5 km
and 7 km from CRUBb
Kintampo North Municipal hospital: 50 m
from KHRC
1 health centre; 30 km from KWTRP
1 county hospital; same location with
KWTRP
Role of primary care
facilities in the MVT
3 health centres: recruitment sites;
patient monitoring; provision of patient
care during and outside working hours;
MVT vaccination centre
1 health centre and 2 dispensaries:
recruitment sites; patient monitoring;
provision of patient care during and
outside working hours; MVT vaccination
centre
2 community clinics: recruitment
sites; patient monitoring; provision of
patient care during and outside
working hours; station for picking and
dropping participants for scheduled
visits at the CRUB
Role of tertiary/
referral facilities in the
MVT
Kintampo North Municipal hospital:
study participants referral and in-patient
care; provide oversight and support for
existing MoH staff in MVT; MVT
vaccination centre
Kiliﬁ County hospital: study participants
referral and in-patient care; provide
oversight and support for existing MoH
staff in MVT
CRUB: study participants referral and
in-patient care; provide oversight and
support for existing MoH staff in MVT;
MVT vaccination centre
Facilities with prior
research/CT
involvement
Kintampo North Municipal hospital,
conducted other inpatient CTs
Kiliﬁ County Hospital, conducted other
inpatient CTs
CRUB, conducted other malaria
vaccine and drug CTs
1 health centre, site within HDSS 2 community clinics, sites within HDSS
Facilities with no prior
research/CT
involvement
2 health centres, sites within HDSS 1 health centre and 2 dispensaries, sites
outside HDSS
*km/m: kilometre/metre;
a CSPS: Centre de Santé et de Promotion Sociale;
b CRUB: clinical research unit of Banfora.
doi:10.1371/journal.pone.0124554.t002
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collection techniques. Sampling procedures were purposive to ensure inclusion of people of dif-
ferent cadre, level of involvement in trial activities and demographic characteristics. The data
sources, sampled facilities and characteristics of interviewees in the three countries are de-
scribed in Table 3.
2.1. Health facility and human resource audits
In each country, all of the facilities (n = 10) involved in the MVT were included in the health
facility audits. Each facility was visited by the research team and a structured checklist was used
to collect data on the presence, functional status (on day of survey) and funding source of labo-
ratory and clinical care equipment, as well as facility infrastructure (such as buildings and vehi-
cles). The human resource audit (n = 144) covered all of the facilities involved in the MVTs
and involved a purposefully selected sample of staff to represent the range and type/cadre of all
staff present in each facility, and research centre staff involved in clinical trials. Data were col-
lected on their primary and secondary responsibilities and whether these were linked to the
malaria vaccine trial, and the type and nature of training received.
2.2. In-depth interviews and focus group discussions
In-depth interviews (IDIs) were undertaken with a range of health care providers and manag-
ers to investigate their experiences and perceptions of the impact of clinical trial activities on
the quality of health care provided at the health facilities. Issues around MVT-MoH linkages
and perceptions of post MVT impact were also explored. IDIs were held with senior investiga-
tors (n = 12), front-line health workers (n = 87) and health mangers (n = 14). All senior investi-
gators with at least one year’s involvement in planning and implementation of the malaria
vaccine trials were approached for interviews, and frontline health workers were purposefully
selected based on their mechanism of employment (MoH staff involved in the trial, MoH staff
not involved in the trial, and MVT employed staff) and their cadre (clinicians, public health of-
ficers, fieldworkers and support staff). We also approached health managers and policy makers
at district, regional and national level with relevant health programme planning and
Table 3. Summary of data collected.
Method Respondent type Ghana Kenya Burkina Faso Total
Non-MVT MVT Non-MVT MVT Non-MVT MVT
Facility auditsa CT facilities 0 4 0 3 0 3 10
Human resource audits MoH staff 5 10 3 6 0 0 24
Research centre staff 23 24 0 5 25 43 120
Investigators interviews Senior CT investigators 0 1 0 1 0 10 12
Health providers interviews MoH staff 9 2 3 6 10 19 49
MVT clinicians 2 14 0 5 3 6 30
MVT ﬁeldworkers 0 0 0 0 0 8 8
Health managers interviews District health managers 4 0 0 0 2 0 6
Regional health managers 2 0 0 0 2 0 4
National health managers 0 0 0 0 4 0 4
Focus group discussion MVT ﬁeldworkers 3 3 0 3 0 0 9
MVT: Malaria vaccine trial
a MVT facilities audited include a referral hospital (Ghana = 1), health centres (Ghana = 3; Kenya = 1), dispensaries (Kenya = 2), community clinics
(Burkina Faso = 2) and a clinical trial facility (Burkina Faso = 1).
doi:10.1371/journal.pone.0124554.t003
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implementation roles, such as Regional hospital mangers, District Health Management Team
(DHMT) members and Maternal and Infant Health programme directors—see Table 3. In ad-
dition, in Kenya and Ghana focus group discussions (n = 9) were conducted with the fieldwor-
kers (employed by the trial to conduct follow-up home visits and liaise between the health
facility and community) in order to gather their views on how the trial inputs affected the func-
tioning of the health facilities.
2.3. Data management and analysis
Each site was responsible for their own data collection and management. For qualitative data,
verbatim transcriptions and back translations were undertaken by the study team in each coun-
try. Across sites the data were managed in NVivo 8 and analysed using a framework approach
[44, 45]. This process involved in-depth reading of transcripts to identify emerging themes
across the datasets, developing a coding framework to code data, generating charts to summa-
rise the data by categories, and data interpretation, to identify differences/similarities and pro-
vide explanations of the analysed data. The quantitative audit data were collated by the study
teams in each country, and entered into Microsoft Excel to generate descriptive summaries.
To facilitate cross-site synthesis and comparison, empty analysis tables were developed
on the basis of an in-depth discussion of preliminary results from each site (one week work-
shop in Ghana). Each site then pulled out all data—qualitative and quantitative—to popu-
late these tables. In a second workshop in Kenya, the data for each site were then collated
and discussed. We employed the World Health Organisation (WHO) health systems build-
ing blocks to aid in the development of our framework for analysis and tables, and in the in-
terpretation of data [46].
2.4. Ethical consideration
Ethical approvals were obtained from national ethics committees of the respective countries
prior to the commencement of study activities (Ghana Health Service and Kintampo Health
Research Center in Ghana; KEMRI National Ethical Review Committee in Kenya; Comité
d’Ethique sur la Recherche en Santé (CERS) and Comité de Bioéthique Institutionnel du
CNRFP (CIB/CNRFP) in Burkina Faso. Separate local ethics clearances were also obtained at
each site. All data were anonymised, with access limited only to researchers. Written informed
consent was obtained from all interviewees. Prior to any data collection, the malaria vaccine
trial staff were briefed about our study, and permission was sought to conduct the work from
health facility staff and opinion leaders. We gave feedback to malaria vaccine trial staff on
emerging issues of importance and shared preliminary results with the MVT teams.
Results
3.1. Inputs to MVT facilities and perceived impact on routine service
delivery
In all three countries, establishing the MVT sites (within local health facilities involved upgrad-
ing and renovating the physical infrastructure, providing medical supplies and equipment, in-
creasing human resources, providing additional funds and training and supporting MVT
participants’medical costs.
i. Physical inputs to facilities. Physical infrastructure. In Ghana, the Kintampo North
Municipal hospital and one of the three health centres had previously been involved in other
KHRC research activities. During the RTS,S phase III trial set-up, the children’s ward in the re-
ferral hospital and child welfare clinics in the three health centres were repainted and the
Clinical Trials Impact on Health Service Delivery in Africa
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patient waiting bay area expanded. In Kenya, the Kilifi County Hospital receives on-going sup-
port from the KWTRP but the 3 rural facilities selected for the RTS,S phase III had minimal
prior engagement with the KWTRP research activities. At the time of MVT set-up, upgrades to
these rural facilities included the construction of additional rooms, expansion of patient wait-
ing bays, new roofing and repainting. In Burkina Faso, the Clinical Research Unit of Banfora
(CRUB) has continued to receive support from pooled funds from the programme to centrally
run its clinical trial activities. During MVT set-up, the CRUB was entirely refurbished and fully
equipped by the CNRFP, although no upgrades were undertaken in the community clinics,
which served as recruitment sites (Table 4).
Across all three countries the renovations undertaken to support the MVT were appreciated
by frontline health staff. Some respondents said that the additional rooms provided extra work-
ing space that could be used during and after MVT activity hours, and that upgrades of existing
structures (such as the children’s wards and patient waiting bays) created a conducive environ-
ment for providers and health facility users. In Kenya for instance, one health care provider
said that during MVT set-up, the facility management requested the MVT team to have one of
the newly constructed rooms converted to a facility delivery room, and this was perceived to
contribute to improved maternal deliveries and staff performance.
. . .when the trial was starting I had a big problem with finding a place to do deliveries for
pregnant mothers, and as government employees we are gauged on our performance annually
on certain services. . .when the trial came we requested they construct for us a room. . .and it
has helped because the community benefits and I am able to report to my employer. . .
(IDI11/MoH with top-up/Kenya)
However, some of the respondents reported concerns linked to the physical location of
MVT activities and capacity within facilities. For instance, in smaller facilities there were con-
cerns of insufficient space for both trial and routine service delivery, potentially leading to
over-crowding, as expressed by this respondent from Kenya:
Table 4. Physical inputs brought by MVTs.
Inputs Ghana Kenya Burkina Faso
Physical
infrastructure
1 children’s ward and 3 child welfare
clinics renovated
2 rooms and 1 extension constructed 6 rooms (ofﬁce) constructed
4 off-road vehicles 3 off-road vehicles 9 off-road vehicles
3 plastic water tanks 1 plastic water tank 1 plastic water tank
2 generators 1 generator
35 Beds 6 Beds
Perceived changes
due to MVT inputs
MVT off-road vehicles facilitated
emergency referrals, ferrying of
medical supplies and patient access
to facilities
MVT off-road vehicles facilitate emergency
referrals, ferrying of medical supplies and
patient access to facilities
MVT off-road vehicles facilitate
emergency referrals, ferrying of medical
supplies and patient access to facilities
Installed generators provide
additional power source to the
referral hospital
Additional MVT constructed rooms created
more space and facilitated provision of other
routine services e.g. vaccination and maternal
deliveries
Installed generators provide additional
power source to the trial facility
Perceived
concerns/
challenges
In smaller facilities, limited space and capacity
for both MVT activities and routine services
Having MVT activities separated from
routine care, limits access to enhanced
services by community members not in
MVTs
doi:10.1371/journal.pone.0124554.t004
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. . .in the same location we [MoH staff] do pregnancy screening, they [MVT team] sometimes
use the room for blinding [investigational product concealment] and administer vaccines.
When a client needs VCT [voluntary counselling and testing] we [MoH staff] use the same
room. . .and yet the same room is our [facility] delivery site. . . (IDI16/MoH with top-up/
Kenya)
Another challenge articulated by some participants was that while there were efforts to ensure
MVT activities were laid out to blend with existing structures not all were successful. For in-
stance, in Burkina Faso there was a concern that the separate construction for MVT activities
limited the access to these enhanced health services for community members not enrolled in
the trial.
Transport infrastructure. Across all three countries MVTs purchased additional off-road
vehicles (ranging between 2 and 9 cars) to facilitate MVT activities at the peripheral MVT
health facilities. Although availability of MVT transport was mainly to facilitate the implemen-
tation of MVT activities, the majority of frontline providers across the three countries felt the
presence and access to MVT vehicles played a big role in supporting routine services. For in-
stance, transportation of essential drugs and other medical supplies, improved patient access to
facilities (allowing for early diagnosis and treatment of illnesses) and assisted with patients’ re-
ferral and community outreach. These inputs were perceived to benefit MVT participants and
non-participants alike.
Medical care support. Across all three countries, the MVTs channelled substantial funding
into the purchase of medical equipment such as laboratory equipment, oxygen cylinders and
examination couches (Table 5). The MVTs ensured there were regular supplies and access to
essential drugs (such as paracetamol, antibiotics, antimalarials and cough syrup) at MVT sites
and clinical equipment (such as thermometers, anthropometric scales, and stethoscopes)
Table 5. Medical care support to MVT facilities.
Inputs Ghana Kenya Burkina Faso
Medical equipment
(selected items)
3 Oxygen cylinders & gas 3 Oxygen cylinders & gas 2 Oxygen cylinders & gas
5 Stethoscopes 6 Stethoscopes 5 Stethoscopes
50 Thermometers 32 Thermometers 18 Thermometers
2 Length boards (<5 years) 3 Length boards (<5 years) 5 Length boards (<5 years)
5 Children weighing scales 6 Children weighing scales 5 children weighing scales
3 Examination coaches 3 Examination coaches 2 Examination coaches
2 Pump and suction machine 2 Pump and suction machine 1 Pump and suction machine
8 Manual suction apparatus 2 Manual suction apparatus 1 Oropharyngeal tube
2 Ambu bags 1 Ambu bag 1 Laryngoscope
2 Cardiac monitors 2 Oropharyngeal tubes 1 Cardiac monitor
1 Digital X-ray machine and printer 1 Laryngoscope
Perceived changes of
procedures/ routine
services due to MVT
Provision of diagnostic kits supported with
training helped improve malaria case
management
Provision of diagnostic kits supported
with training helped improve malaria
case management
Provision of diagnostic kits supported
with training helped improve malaria
case management
Access to equipment for improving
emergency care in rural facilities
Access to equipment for improving
emergency care in rural facilities
Access to equipment for improving
emergency care in rural facilities
Improved radiology services in hospitals
for all users
Improved radiology services in
hospitals for all users
Standard clinical practise to screen all
febrile children for malaria and
bacteraemia on admission, in all MVT
facilities
doi:10.1371/journal.pone.0124554.t005
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where needed for routine patient clinical care (Table 5). Audit data indicate that in Ghana and
Burkina Faso, hospitals and clinical trial units received more clinical care equipment than pe-
ripheral health facilities; by contrast in Kenya, there was more support to dispensaries and
health centres. This difference is likely to have been due to the different roles of these facilities
in MVT related activities and the additional inputs to facilities to help meet MVT
site standards.
Most MoH health providers appreciated the improved access to essential drugs provided by
the MVTs. Some MoH staff said the availability of malaria diagnostic kits and training in their
use help them adhere to treatment guidelines rather than treating malaria presumptively, while
others suggested there had been a general reduction in malaria morbidity and mortality due to
MVT activities.
. . .were it not for the study child [participant], you would have treated them clinically [pre-
sumptively]. . .but because we have been given kits [malaria RDTs], you test them and at least
you feel that you have done something good. (IDI20/MoH with top-up/Kenya)
In addition, in the past most facilities had challenges handling emergency care, hence the
availability of oxygen cylinders and gas donated by MVTs to peripheral and tertiary health fa-
cilities, was reported to enable clinicians help resuscitate sick patients. Furthermore, in Ghana
the availability of digital x-rays was perceived as a major boost to the hospital and due to the
presence of MVT activities, it became standard practice to screen all febrile children for malaria
and bacteraemia on admission in all MVT facilities.
ii. Human resource inputs to facilities in each country. Staffing. In all three countries
additional full time staff were hired during the MVT period to assist with patient clinical care
at the MVT peripheral health facilities (Table 6). These included study clinicians (doctors,
nurses and clinical officers) who were hired to provide clinical care and administer MVT vac-
cines to study participants; and fieldworkers, who were employed from local communities
where MVTs were conducted to assist in conducting follow-up home visits. In MVT facilities,
existing MoH clinical staff were also employed on a locum basis, or provided salary top-ups to
assist with the provision of clinical care, especially to study participants during and out-of facil-
ity working hours.
Across all three countries, the majority of respondents appreciated the additional health
workers employed by MVTs, as they were perceived to contribute to a reduction in workload
for MoH health workers. For instance, MVT clinicians supported with all paediatric patient
consultation during busier clinic days in MVT primary care facilities or while the nurse in-
charge/MoH clinicians were absent from the facility (while attending official meetings—all
three countries, and during the nationwide health workers strike—Kenya only). In Kenya and
Ghana, MVT clinicians regularly supported MoH clinicians with the administration of routine
childhood vaccines alongside MVT vaccines.
. . .we [MoH staff] are over-stretched and we don’t have a lot of staff; so when they [MVT
staff] go [to health facilities], they also assist with some of the routine aspects of the OPD [out-
patient department] cases and other cases.We are able to take lessons and pass it on to the
other [MoH] nurses. . . (IDI/MoH without top-up/Ghana)
The facility staff and some trial frontline staff also reported that MVT staff at MVT periph-
eral facilities provided supportive supervision, acted as role models and could easily be ap-
proached to seek clinical advice/consultation. Most of these respondents felt the good working
relationship that existed between trial and MoH staff facilitated a good learning environment.
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With the presence of CNRFP workers [nurses] in the facility, the behaviour of other health
workers has changed. They are more attentive towards patients and are more careful in filling
in [information in clinic] books, even when they are not those CRFs [case report forms] of
CNRFP. (IDI44/MoH without top-up/Burkina Faso)
By contrast, across all three countries, some staff (among all cadres and types of employ-
ment) felt MVT activities had led to an increase in their workload, through adding new activi-
ties such as filling in MVT forms, having to work for extra hours, and performing extra chores
without pay. The latter concerns were raised particularly by trial fieldworkers and MoH non-
trial staff.
Training. In all three countries, the MVTs provided training in good clinical practice
(GCP), good laboratory practice (GLP) and health research ethics (HRE). However, the train-
ing provided varied across the countries by cadre of MoH staff and according to level of in-
volvement in trial related activities. For instance, in Ghana and Kenya, MoH clinical staff
involved in trials were provided with training but non-clinical staff were excluded. By contrast,
Table 6. Human resource input by MVTs.
Inputs/ incentives Ghana Kenya Burkina Faso
Full time MVT staff
(primary care facilities)
114 project staff (13 doctors, 60
ﬁeldworkers)
59 project staff (2 doctors, 5 clinical
ofﬁcers, 4 nurses, 29 ﬁeldworkers)
68 project staff (10 doctors, 12 nurses,
16 ﬁeldworkers)
MoH staff paid MVT
salary/top-up (primary
care facilities)
23 MoH staff (nurses and community
health ofﬁcers)
12 MoH staff (1 clinical ofﬁcer, 11
nurses)
20 MoH staff (16 nurses, 4 Lab
assistants)
MoH staff paid MVT
salary/top-up (referral
hospitals)
13 MoH staff (paediatricians, doctors
and other health professionals)
2 MoH staff (Paediatricians/doctors)
MoH staff not paid MVT
salary/top-up (primary
care facilities)
80 MoH non-clinical staff 26 MoH staff: Public Health Ofﬁcers,
Pharmacy aide(s), support staff
6 MoH staff: pharmacy aide(s), guards
MoH training and who
considered (primary care
facilities)
GCP, GLP and vaccine cold-chain
management; MoH clinical staff
GCP, GLP, communication and
research ethics; MoH clinical staff
GCP and GLP; MoH clinical and non-
clinical staff
Perceived changes of
procedures or routine
services due to MVT
(primary care facilities)
Presence of MVT activities led to
extended facility operational hours
Presence of MVT activities led to
extended facility operational hours
Presence of MVT activities led to
extended facility operational hours
Constant availability of qualiﬁed
medical staff improves disease
surveillance and facilitate learning (for
MoH staff)
Constant availability of qualiﬁed medical
staff improves disease surveillance and
facilitate learning (for MoH staff)
Constant availability of qualiﬁed medical
staff improves disease surveillance and
facilitate learning (for MoH staff)
MoH clinicians trained on cold-chain
management able to support MVT
vaccination
MVT vaccines administered in the same
location with routine childhood vaccines,
strengthening integration and learning.
MVT clinicians assist with routine
childhood vaccination
Perceived concerns/
challenges
Additional workload due to MVT
activities—ﬁlling MVT forms, working
extra hours, providing back-up roles
without pay (MoH non-trial staff)
Additional workload due to MVT
activities—ﬁlling MVT forms, working
extra hours, providing back-up roles
without pay (MoH non-trial staff)
Additional workload due to MVT
activities—ﬁlling MVT forms, working
extra hours, providing back-up roles
without pay (MoH non-trial staff)
Some MoH non-trial staff feel
excluded in consideration of MVT
training and allowances
Some MoH non-trial staff feel excluded
in consideration of training and
allowances
MoH staff lack supportive supervision
once trained, need additional training to
handle MVT purchased medical
equipment, and high-staff turnover
requires constant further training for
newly posted MoH staff
* GCP; Good clinical practice; GLP: Good Laboratory Practice—including training in microscopy use; MoH: Ministry of Health.
doi:10.1371/journal.pone.0124554.t006
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in Burkina Faso, all staff at the community clinics involved in the trial received training. In
most instances, the majority of the MoH frontline providers had minimal prior research expe-
rience and the training provided by the MVTs were organised during site initiation and when
new MoH staff were posted to MVT facilities. In general, access to training was perceived to be
an individual benefit and a benefit for the patients through improvements in the quality of
care provided.
All the staff involved with patient care in our health facility were trained on microscopy
use. . .and how to perform RDTs [rapid diagnostic tests]. In district meetings, we [MoH staff
in MVT facilities] are considered privileged. . . (IDI40/MoH with top-up/Burkina Faso)
However, there were mixed perceptions regarding the nature, practicality and relevance of
the MVT related training. For instance, participants in Burkina Faso expressed concern that
staff were trained on GCP but lack supportive supervision and in Kenya one of the respondents
found the training ‘complex’ and would need to reconsider attending a refresher course. In
Burkina Faso concerns were raised about the amount of training needed to handle new MVT
purchased medical equipment (such as haematology analysers), particularly since high staff
turn-over invariably meant further training for newly posted MoH staff.
iii. Health financing and perceptions of input. MoH staff incentives. In all three coun-
tries, the MVTs provided salary top-up or allowances to existing MoH staff (including paedia-
tricians, nurses, doctors) at peripheral and referral health facilities to support various aspects of
MVT activities (see Table 6). For instance health managers provided oversight and support su-
pervision to MoH staff in MVT facilities, while MoH clinicians provided care to study patients
during and out-of work hours. However, the calculation of payment varied by country. In
Ghana, it was based on number of hours worked and in Kenya, it was calculated as a fixed pro-
portion of the monthly salary. In Burkina Faso, it was based on involvement in specific trial ac-
tivities. There were also country variations in who was eligible for a salary top. For instance, in
Ghana and Kenya only MoH staff providing clinical care were included while in Burkina Faso,
all MoH staff, irrespective of their cadre/specialization were included.
. . . the project [MVT] pays monthly to the facility the amount corresponding to the total num-
ber of filled files. Then the in-charge redistributes this amount to all facility staff so that each
staff gains something, even the guard and the essential drugs deposit staff. This [approach]
seems more equitable to us [facility staff]. (IDI31/MoH with top-up/Burkina Faso)
The mechanism of rewarding staff generated mixed reactions. In all three countries, most
MoH clinical staff receiving a salary top-up reported that their standards of living had im-
proved (particularly compared to their MoH colleagues not involved in MVTs) and they felt
motivated to perform better. These sentiments were echoed in interviews with trial staff.
Regularly giving them “something” [top-up] motivates MoH staff in the peripheral health fa-
cilities participating in CTs. Not only do they work well, but they also work regularly. . .the
output is quite different. . . (IDI01/trial staff/Burkina Faso)
However, MoH frontline staff in all three countries also reported challenges with the MVT
reward mechanisms. Some of the MoH clinical staff receiving a top-up felt their pay compared
poorly to trial clinicians even though they performed similar roles. Many MoH staff not receiv-
ing a top-up were unhappy that they were excluded from this benefit despite providing back-
up to their colleagues where needed.
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Facility operational cost. The MVTs covered some of the operational costs incurred by the
MVT peripheral health facilities including a monthly fuel and communication allowance in
Ghana and Kenya, and an internet connection to the referral hospital in Ghana and the CRUB
in Burkina Faso. These inputs improved the connectivity of the peripheral facilities, enhancing
their ability to manage their drugs supplies and obtain support in clinical decision making. In
Kenya, the dispensaries were able to charge the MVT for the user-fee payments that they
would have otherwise received from the MVT participants when they visited the facility. Given
the relatively high use of facilities by trial participants (encouraged by the MVT staff) these
funds contributed to increased facility funding, allowing for the payment of support staff sala-
ries and the purchase of supplies like gloves.
. . .so in one of the dispensaries. . .we [MVT and facility staff] had to agree that any partici-
pant seen will be recorded and pay their user fee on a monthly basis. . .so it’s a small income
for the dispensary. . .and they use the money to pay subordinate staff and sustain services
within that dispensary. (IDI24/trial staff/Kenya)
3.2 What happens when MVTs are concluded
In interviews with health workers and managers, we explored their perceptions of the potential
impact of the ending of the MVTs and the withdrawal of staff and other inputs on staff and ser-
vice delivery in facilities where MVTs were implemented. We discuss their views and sugges-
tions for MVT exit.
i. Equipment and infrastructure. The participants were ambiguous about the potential
post-trial benefits and challenges associated with the equipment and infrastructure brought to
the facilities by the MVTs. Many were unsure of what would be left behind and, if equipment
was left behind, who would be responsible for maintenance. In all three countries concerns
were raised over MoH capacity (financial and technical) to handle and maintain equipment
after trial closure.
. . .these days facilities don’t generate income and it would be very difficult for them to take
good care. . .or provide maintenance to their structures. . ..any money that comes to the sys-
tem is programmed. . .so getting funds to maintain the clinical trial infrastructure would be
difficult. (IDI/MoH without top-up/Ghana)
In addition, some MoH frontline staff suggested that before the closure of the trial consider-
ation should be given to providing additional support such as facility upgrades, or donation of
funds to a facility kitty to assist with facility operations post-trial.
ii. Staffing and employment. In all three countries, fieldworkers and MoH clinicians re-
ported concerns about loss of employment and earnings, with negative implications for staff
morale and facility workload.
. . .there will be a very big gap. The cadre of professionals who were working here. . .like medi-
cal officers at dispensary level is something that rarely happens in our country. . .we get a lot
of assistance from them [trial]. . . (IDI16/MoH with top-up/Kenya)
iii. Facility service delivery. It was universally perceived that withdrawal of MVT staff
and services (transport and drug supply) would lead to a significant deterioration in facility ser-
vices including longer queues/waiting time, increased MoH staff workload, and a return to
drug-shortages and problems with facility access.
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When the study leaves our hands will be chopped! Because when we ran out of supplies, they
[MVT] bring for us. . ..if they leave we will suffer. . . (IDI20/MoH with top-up/Kenya)
Other dilemmas expressed especially by fieldworkers and MoH staff were how to handle
community expectations. In particular, they felt participants and their families would face
problems meeting their health care costs, and that this could impact on their treatment seeking
patterns.
. . . Mothers will go back to their initial habits of delaying to seek care in facilities when their
child is sick, because they lack money to buy drugs. . .when the trial ends and there is no free
care,mothers will opt to stay at home when their children are sick. (IDI28/trial staff/Burkina
Faso)
Discussion
The potential benefits and consequences of clinical trials on communities and facilities in
which they are implemented has led to calls for more empirical work to understand how CTs
impact health service delivery in Africa. In this paper, we draw on quantitative and qualitative
data from studies of MVTs in Ghana, Kenya and Burkina Faso to explore health providers’ per-
ceptions of the impact of malaria vaccine trials on routine health service delivery, and the quali-
ty of care provided.
There was considerable heterogeneity in the way in which trial centres were established and
in the implementation of the malaria vaccine trials across the study sites and trials. However,
all three trials provided considerable inputs into the public health facilities in which they were
based. Our findings, in common with those of other studies [9, 10, 13, 18, 20], suggest that CTs
have the potential to benefit facilities through infrastructure upgrades, the provision of medical
care support and additional qualified personnel, and by supporting some facility operational
costs. For instance, the availability of transport provided by the trials supported facility referral
services, the increased interconnectivity allowed for support to decision making and increased
opening hours with extra staff allowed for improved patient access to health care. The constant
availability of essential drugs also helped to address the drug shortage problems faced in many
sub-Saharan African settings.
Across all the three countries, the MVTs provided salary top-up and training to existing
frontline staff to assist with MVT activities and provide routine care. The MoH staff perceived
that the additional wages helped them improve their standard of living and motivation. How-
ever, our findings also suggest that all of the different reward mechanisms employed across the
countries (only paying MoH clinical staff in Ghana and Kenya versus paying all facility staff ir-
respective of their cadre in Burkina Faso) generated dissatisfaction and relationship challenges
among some frontline staff, and had the potential to demotivate those staff not involved in the
process. Similar dilemmas were reported in a Cameroon trial on the use of mobile phone re-
minders among HIV patients receiving treatment from a referral hospital [13]. In a context
where facility staff wages are often low, several authors have suggested that to avoid perverse
outcomes, CTs need to ensure that the reward mechanisms are fair and considered alongside
other non-financial incentives such as training and improved working environment. These au-
thors have also pointed out that any rewards have to be balanced against the risk of escalating
trial budget costs and the potential to undermine more intrinsic forms of health worker moti-
vation such as altruism and social recognition [9, 12, 13, 24]. The data from this study suggest
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that even if negative effects of these rewards are not experienced at the time of the trial, their
withdrawal once the study has concluded could have harmful effects on staff morale and ulti-
mately patient care.
Uncertainty over what would happen once the MVTs were concluded was an emerging con-
cern among participants across all three countries. The large majority of participants were of
the opinion that the ending of the trial would have a negative impact on staff through loss of
wages, with facility services deteriorating due to a recurrence of drug shortages, lack of trans-
port for referrals and increased workload due to the removal of additional staff. There were
also concerns about whether or not MVT equipment and infrastructure would be left behind
and, if it were, who would be responsible for its maintenance. Such fears have been found in
other studies of the impact of CTs [8, 11, 47] suggesting a lack of capacity and confidence
among MoH implementers to maintain some of the positive changes experienced during trial
period. There are particular concerns if there is a potential for remaining staff and facilities to
be left ‘worse off’ than before the trial began, as a result of raised expectations being dashed, or
new non-essential costs being introduced that cannot be maintained.
In addition to the infrastructural inputs, CTs invest in training and capacity building of
frontline staff, to ensure that standards of care provided meet local and international standards
[1, 6, 7, 11]. In this study we found that, on the whole, the training provided by the MVTs was
perceived to be beneficial. However, across the countries different strategies were adopted for
the selection of staff for training and staff excluded from training expressed concerns about
their omission. These feelings of marginalization were particularly acute among non-clinical
staff and may impact on performance. A recent study in Kenya found that a lack of fairness in
attending seminars or other training opportunities, and limited opportunities for career ad-
vancement, affected health workers performance and motivation [48]. In our study, among the
MoH staff who had received GCP training there was also dissatisfaction with the lack of subse-
quent supportive supervision, although training was provided for any new staff who joined the
clinic during the lifetime of the MVT. This happened fairly frequently because, as elsewhere in
sub-Saharan Africa [24, 49], staff turnover in rural health facilities in all three countries was
high. Our data suggest that CTs should carefully consider the nature of the training that they
provide to trial and facility staff. Training that is relevant to service provision for all users of
trial facilities—including in technical care provision but also, for example, in governance and
oversight of facilities—has the potential to have a positive impact on a wide range of users and
the staff themselves in their current and future careers.
The inputs and strategies employed by the three MVTs involved in this study to ensure the
provision of quality health care to trial participants were, perhaps unsurprisingly, very similar
to the health system strengthening interventions implemented in many countries in sub-
Saharan Africa in an attempt to improve the quality of patient care. Data from evaluations of
such interventions suggest that continuous education and training are critical in motivating
frontline staff and improving performance [3, 12, 24, 49] but that any improvements disappear
quickly if no follow-up support is provided [50–55]. Furthermore, recent research suggests that
changing health worker practices requires the development and maintenance of a supportive
community of practice [56, 57]. Our data suggest that the presence of MVT clinicians in the
health facilities for the duration of the trial and the enhanced communication facilitated by the
trial inputs and activities helped to provide a community of practice that enabled non-trial cli-
nicians to improve the quality of care they provided. However, our interview data suggest that
the non-trial clinicians had little confidence in their ability to maintain these practices once the
trial concluded and the ‘trial clinician community’ was disbanded.
CTs may, in the short term and for the duration of the trial, be able to provide the elements
and conditions (such as training, support supervision, enhanced community of practice, and
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supplies of drugs) under which frontline health workers are able to improve their practices.
However, as the data from this and other studies suggest, maintaining new practices requires
system related changes that lie outside the realm of individual health workers or health facilities
[51, 56–59], and many complex interventions have been developed and implemented over re-
cent years in an attempt to facilitate such change, with varying levels of success [51, 52, 55, 60,
61]. We would argue that while CTs mimic the inputs of health system strengthening interven-
tions, they are not designed as such and cannot take on this role. On the other hand, where
they do operate alongside the frontline provision of care, trialists need to be aware of their po-
tential impact on health worker motivation and behaviour and should take note of the lessons
provided by the health systems strengthening literature in the design of strategies for
CT implementation.
Recommendations for future clinical trials
While CTs are clearly not designed as health system strengthening interventions we suggest
that there are steps that trials can take to help ensure that they leave behind positive rather
than negative impacts. We suggest the need for CTs to ensure they have a clearly documented
memorandum of understanding (MoU) with MoH managers and facility staff at the onset to
identify the level of CT support required, and develop a strategy for staggered exit and hand-
over of responsibilities and equipment to MoH or other key local actors when CTs end. Such a
process could help identify each stakeholder’s responsibility including maintenance issues and
should include a process of negotiation to handle any unmet expectations. In the early post
trial period, CTs could consider maintaining some staff to help monitor and provide support
in addressing post-trial issues. Careful documentation and evaluation of different exit strategies
would be valuable to the planning of future trials, while recognising the limits of the health de-
livery responsibilities that trials can and should take on during and after trials. The latter is par-
ticularly important given both the need for locally appropriate, ethically conducted, trials in
the region, and the potential for escalating costs and bureaucratic requirements to undermine
the ability of such trials to be conducted.
Limitations
The focus of this study was malaria vaccine trials based in peripheral health facilities and dis-
trict hospitals. While some of the inputs recorded are likely to be specific for malaria preven-
tion or treatment trials (e.g. antimalarial drugs and malaria rapid diagnostic tests), our long
experience of clinical trials based in similar settings in sub-Saharan Africa suggests that many
of the key inputs, such as salary top-ups for staff, staff training, enhanced communication, and
physical infrastructure improvements, are common across a range of clinical trial types. Fur-
thermore, our findings echo those from other studies on the impact of individual clinical trials
and, in this study, the use of similar tools across heterogeneous contexts (country, research cen-
tres and type of facilities) and diverse respondents (trial staff, MoH frontline providers and
health managers) has enabled us to paint a broad description of health provider perceptions of
the effects on service provision of hosting a clinical trial in low resource settings. A potential
constraint in data collection (particularly the in-depth interviews) was the association between
the study research teams and the clinical trial teams in each country. The study research teams
were from the same institution as the trial implementing teams and, while the research team
were independent of the trial team, it is possible that knowledge of this relationship influenced
interview responses.
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Conclusion
Clinical trials inputs have the potential to improve health service delivery and benefit the facili-
ties, staff and communities involved in clinical trials. However, there are limits to the wider
health system benefits that can be expected and achieved through trials and unexpected and
unintended negative consequences can occur both during the lifetime of the trial and after the
trial has been completed. While clinical trials should not be expected to fill the role of health
service strengthening interventions, our findings suggest that to strengthen ethical practice,
consideration of some of the potential benefits and harms to the wider health system need to
be considered from the outset and discussed with key local stakeholders and funders. Such dis-
cussions are likely to need to be revisited and revised throughout the trial, as well as immediate-
ly post completion, as part of wider trial planning and community engagement strategies, and
in response to emerging issues.
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